| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7399865 | PUMA BIOTECH | Protein tyrosine kinase enzyme inhibitors |
Dec, 2030
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7982043 | PUMA BIOTECH | Protein tyrosine kinase enzyme inhibitors |
Oct, 2025
(2 years from now) | |
| US9630946 | PUMA BIOTECH | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
Oct, 2028
(5 years from now) | |
| US9139558 | PUMA BIOTECH | Maleate salts of (E)-N-{4-[3-Chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
Oct, 2028
(5 years from now) | |
| US10035788 | PUMA BIOTECH | Maleate salts of (E)-N-{4[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
Oct, 2028
(5 years from now) | |
| US9265784 | PUMA BIOTECH | Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine |
Aug, 2029
(5 years from now) | |
| US9211291 | PUMA BIOTECH | Treatment regimen utilizing neratinib for breast cancer |
Mar, 2030
(6 years from now) | |
| US8790708 | PUMA BIOTECH | Coated tablet formulations and uses thereof |
Nov, 2030
(7 years from now) | |
| US8518446 | PUMA BIOTECH | Coated tablet formulations and uses thereof |
Nov, 2030
(7 years from now) | |
| US8669273 | PUMA BIOTECH | Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine |
Jul, 2031
(7 years from now) | |
Nerlynx is owned by Puma Biotech.
Nerlynx contains Neratinib Maleate.
Nerlynx has a total of 10 drug patents out of which 0 drug patents have expired.
Nerlynx was authorised for market use on 17 July, 2017.
Nerlynx is available in tablet;oral dosage forms.
Nerlynx can be used as use in combination with capecitabine, for the treatment of adult patients with advanced or metastatic her2-positive breast cancer who have received two or more prior anti-her2 based regimens in the metastatic setting, extended adjuvant treatment of adult patients with early-stage human epidermal growth factor receptor 2 (her2)-positive breast cancer, to follow adjuvant trastuzumab based therapy; use in combination with capecitabine, for the treatment of adult patients with advanced or metastatic her2-positive breast cancer who have received two or more prior anti-her2 based regimens in the metastatic setting; extended adjuvant treatment of adult patients with early stage her2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab base therapy, extended adjuvant treatment of adult patients with early stage her2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab base therapy; use in combination with capecitabine, for the treatment of adult patients with advanced or metastatic her2-positive breast cancer who have received two or more prior anti-her2 based regimens in the metastatic setting; extended adjuvant treatment of adult patients with early-stage human epidermal growth factor receptor 2 (her2)-positive breast cancer, to follow adjuvant trastuzumab based therapy, extended adjuvant treatment of adult patients with early stage her2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab base therapy; extended adjuvant treatment of adult patients with early-stage human epidermal growth factor receptor 2 (her2)-positive breast cancer, to follow adjuvant trastuzumab based therapy; use in combination with capecitabine, for the treatment of adult patients with advanced or metastatic her2-positive breast cancer who have received two or more prior anti-her2 based regimens in the metastatic setting, extended adjuvant treatment of adult patients with early stage her2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab base therapy; extended adjuvant treatment of adult patients with early-stage human epidermal growth factor receptor 2 (her2)-positive breast cancer, to follow adjuvant trastuzumab based therapy.
The generics of Nerlynx are possible to be released after 18 July, 2031.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication (I) | Feb 25, 2023 |
| New Dosing Schedule (D) | Jun 28, 2024 |
Drugs and Companies using NERATINIB MALEATE ingredient
Market Authorisation Date: 17 July, 2017
Treatment: Extended adjuvant treatment of adult patients with early stage her2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab base therapy; Use in combination with capecitabine, for the tr...
Dosage: TABLET;ORAL
NERLYNX family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic